Beyond the biotech IPO: a brave new world.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19668174.
- Also identified by DOI 10.1038/nbt0809-705.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
After a decade of significant challenges, biotech's long-term sustainability depends on making fundamental changes to its traditional business model.
Medical subject headings
- Biotechnology
- Commerce